Training in Neurotherapeutics Discovery and Development for Academic Scientists
Thanks to all students and faculty who participated in Training in Neurotherapeutics Discovery and Development for Academic Scientists - 2013, which was held in conjunction with the 15th Annual Meeting of the American Society for Experimental NeuroTherapeutics in Bethesda, Maryland.
The short course will be offered again Wednesday, February 19 to Saturday, February 22, 2014. The application deadline is Tuesday, October 1, 2013.
About This Training Program
We are happy to offer a 3½-day short course to introduce academic researchers to the principles of neurotherapeutic drug discovery and development. The first highly successful offering of the course was held February 27 to March 2, 2013. A second offering of the course will be held in 2014 in conjunction with the 16th Annual Meeting of the American Society for Experimental NeuroTherapeutics (Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road
North Bethesda, MD 20852; February 20-22, 2014). Participants who have attended the short course program will have ongoing access to senior faculty who will assist the trainee to achieve success in their individual drug development projects.
You will find the course useful if you would like to learn how molecules to treat disorders of the nervous system are identified and evaluated prior to entering clinical trials. The course will be especially relevant if you conduct basic neuroscience research and would like to compete for the many new translational grant opportunities that are available.
The course covers the principles of drug discovery and development, including the identification of a lead compound and IND enabling studies. The course will also address the unique challenges inherent in developing treatments for nervous system disorders and will address the particular challenges that academic neuroscientists are likely to face in planning and conducting drug discovery research. Please note, however, that the course curriculum does not address clinical trials.
Although we anticipate that most applicants will be advanced postdoctoral fellows or junior faculty members, any academic investigator who would benefit from the course is invited to apply. Basic researchers and clinician scientists are eligible. There is no tuition or registration fee and travel expenses will be defrayed for all successful applicants. The course will be offered annually for three additional years.
We are excited to have the opportunity to offer this course, which we believe will help to advance the availability of new drugs for patients with neurological and psychiatric disorders. If your work would benefit from an understanding of how neurotherapeutic drugs are discovered, characterized and tested so that they can enter clinical trials, you are encouraged to apply.
Michael A. Rogawski, MD, PhD
Barbara Slusher, PhD
Marcie Glicksman, PhD
Karl Scheidt, PhD
Course Directors
Supported by National Institute of Neurological Disorders and Stroke Grant 1R25NS077582
North Bethesda, MD 20852; February 20-22, 2014). Participants who have attended the short course program will have ongoing access to senior faculty who will assist the trainee to achieve success in their individual drug development projects.
You will find the course useful if you would like to learn how molecules to treat disorders of the nervous system are identified and evaluated prior to entering clinical trials. The course will be especially relevant if you conduct basic neuroscience research and would like to compete for the many new translational grant opportunities that are available.
The course covers the principles of drug discovery and development, including the identification of a lead compound and IND enabling studies. The course will also address the unique challenges inherent in developing treatments for nervous system disorders and will address the particular challenges that academic neuroscientists are likely to face in planning and conducting drug discovery research. Please note, however, that the course curriculum does not address clinical trials.
Although we anticipate that most applicants will be advanced postdoctoral fellows or junior faculty members, any academic investigator who would benefit from the course is invited to apply. Basic researchers and clinician scientists are eligible. There is no tuition or registration fee and travel expenses will be defrayed for all successful applicants. The course will be offered annually for three additional years.
We are excited to have the opportunity to offer this course, which we believe will help to advance the availability of new drugs for patients with neurological and psychiatric disorders. If your work would benefit from an understanding of how neurotherapeutic drugs are discovered, characterized and tested so that they can enter clinical trials, you are encouraged to apply.
Michael A. Rogawski, MD, PhD
Barbara Slusher, PhD
Marcie Glicksman, PhD
Karl Scheidt, PhD
Course Directors
Supported by National Institute of Neurological Disorders and Stroke Grant 1R25NS077582
